CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement

Journal of Clinical Oncology

Volumn 34, Issue 2, 2016, Pages 107-109

  Shi, Wenyin ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BRIGATINIB; CERITINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; LORLATINIB; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

BRAIN METASTASIS; BRAIN RADIATION; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; COGNITIVE DEFECT; EDITORIAL; EXECUTIVE FUNCTION; GENE REARRANGEMENT; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOSURGERY; STEREOTACTIC RADIOSURGERY; BRAIN NEOPLASMS; FEMALE; GENETICS; LUNG TUMOR; MALE; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; SECONDARY; SKULL IRRADIATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CRANIAL IRRADIATION; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; RADIOSURGERY; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84954325021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.9682     Document Type: Editorial

References (31)

1. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
2. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
3. Solomon BJ, Mok T, Kim DW, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
4. Shaw AT, Kim DW, Mehra R, et al: Ceritinib in ALK-rearranged non-smallcell lung cancer. N Engl J Med 370:1189-1197, 2014
5. Rangachari D, Yamaguchi N, Vander Laan PA, et al: Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88:108-111, 2015
6. Costa DB, Shaw AT, Ou SH, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881-1888, 2015
7. Johung KL, Yeh N, Desai NB, et al: Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123-129, 2016
8. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997
9. Sperduto PW, Berkey B, Gaspar LE, et al: A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510-514, 2008
10. Sperduto CM, Watanabe Y, Mullan J, et al: A validation study of a new prognostic index for patients with brain metastases: The Graded Prognostic Assessment. J Neurosurg 109:87-89, 2008 (suppl)
11. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
12. Guo S, Reddy CA, Chao ST, et al: Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77:389-393, 2012
13. Eichler AF, Kahle KT, Wang DL, et al: EGFR mutation status and survival after diagnosis of brain metastasis in non-small-cell lung cancer. Neuro Oncol 12: 1193-1199, 2010
14. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus wholebrain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 295:2483-2491, 2006
15. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
16. Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011
17. Sahgal A, Chuang C, Larson D, et al: Split-volume treatment planning of multiple consecutive vertebral body metastases for cyberknife image-guided robotic radiosurgery. Med Dosim 33:175-179, 2008
18. Yamamoto M, Serizawa T, Shuto T, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 15:387-395, 2014
19. Brown PD, Pugh S, Laack NN, et al: Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429-1437, 2013
20. Gondi V, Pugh SL, Tome WA, et al: Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 32:3810-3816, 2014
21. Friboulet L, Li N, Katayama R, et al: The ALK inhibitor ceritinib overcomes crizotinib resistance in nonsmall-cell lung cancer. Cancer Discov 4:662-673, 2014
22. Kim D, Mehra-R, Tan D, et al: Ceritinib in advanced anaplastic lymphoma kinase (ALK) -rearranged (ALK1) non-small-cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 8003)
23. Gadgeel SM, Gandhi L, Riely GJ, et al: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALKrearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119-1128, 2014
24. Gettinger S, Bazhenova L, Salgia R, et al: Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK1 non-small-cell lung cancer (NSCLC). J Clin Oncol-32:5s, 2014 (suppl;abstr 8047)
25. Johnson TW, Richardson PF, Bailey S, et al: Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno) pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALKresistant mutations. J Med Chem 57:4720-4744, 2014
26. Gainor JF, Sherman CA, Willoughby K, et al: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10:232-236, 2015
27. Dai Y, Wei Q, Schwager C, et al: Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Radiother Oncol-114:173-181, 2015
28. Sun Y, Nowak KA, Zaorsky NG, et al: ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small-cell lung cancer expressing EML4-ALK. Mol Cancer Ther 12:696-704, 2013
29. Weickhardt AJ, Scheier B, Burke JM, et al: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Onco 7:1807-1814, 2012
30. Sperduto PW, Wang M, Robins HI, et al: A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small-cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85: 1312-1318, 2013
31. Takeda M, Okamoto I, Nakagawa K: Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8:654-657, 2013